Premium
Veracyte Inc (VCYT)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Mr. Jonathan WygantVP & CAO | -24,00k | 494,42k | Derivative Exercise and Sale | 24,80 - 45,40 | 7,87k | - |
| 2026-05-20 | Dr. Robert S. EpsteinIndependent Chair | -10,00k | 440,13k | Automatic Disposition | 44,01 | 43,13k | -18,82% |
| 2026-05-06 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,20k | 398,21k | Automatic Disposition | 38,05 - 40,00 | 1,13k | -90,02% |
| 2026-03-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,66k | 236,72k | Automatic Disposition | 35,29 - 36,34 | 11,34k | -37,00% |
| 2026-03-04 | Ms. Rebecca ChambersExec. VP & CFO | -18,34k | 662,87k | Automatic Disposition | 35,55 - 36,33 | 36,20k | -33,63% |
| 2026-03-04 | Mr. Marc A. StapleyCEO & Director | -45,52k | 1,64M | Automatic Disposition | 35,56 - 36,28 | 143,90k | -24,03% |
| 2026-03-04 | Dr. John LeiteGlobal Chief Commercial Officer | -5,26k | 185,08k | Automatic Disposition | 35,19 | 18,38k | -22,25% |
| 2026-03-02 | Mr. Marc A. StapleyCEO & Director | -19,46k | 700,57k | Sale to Issuer | 36,01 | 189,42k | -9,31% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -13,43k | 485,43k | Automatic Disposition | 36,16 | 32,06k | -29,51% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -6,04k | 217,32k | Sale to Issuer | 36,01 | 32,06k | -15,84% |
| 2026-03-02 | Dr. John LeiteGlobal Chief Commercial Officer | -7,52k | 270,69k | Sale to Issuer | 36,01 | 23,64k | -24,13% |
| 2026-03-02 | Ms. Rebecca ChambersExec. VP & CFO | -7,23k | 260,50k | Sale to Issuer | 36,01 | 54,54k | -11,71% |
| 2026-03-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,90k | 248,54k | Sale to Issuer | 36,01 | 17,99k | -27,72% |
| 2026-03-02 | Mr. Jonathan WygantVP & CAO | -3,01k | 108,25k | Sale to Issuer | 36,01 | 7,87k | -27,64% |
| 2026-02-26 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -24,49k | 948,83k | Sale to Issuer | 38,75 | 39,67k | -38,17% |
| 2026-02-26 | Ms. Rebecca ChambersExec. VP & CFO | -12,05k | 466,90k | Sale to Issuer | 38,75 | 47,56k | -20,21% |
| 2026-02-26 | Dr. John LeiteGlobal Chief Commercial Officer | -8,91k | 345,07k | Sale to Issuer | 38,75 | 16,39k | -35,21% |
| 2026-02-26 | Mr. Marc A. StapleyCEO & Director | -35,84k | 1,39M | Sale to Issuer | 38,75 | 170,64k | -17,36% |
| 2026-02-26 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,87k | 421,10k | Sale to Issuer | 38,75 | 11,34k | -48,94% |
| 2025-12-16 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10,74k | 463,20k | Automatic Disposition | 43,13 - 43,68 | 758,00 | -93,41% |
| 2025-12-05 | Ms. Karin EasthamIndependent Director | -20,00k | 753,52k | Derivative Exercise and Sale | 7,60 - 46,59 | 4,23k | - |
| 2025-12-04 | Mr. Marc A. StapleyCEO & Director | -7,67k | 361,08k | Automatic Disposition | 46,90 - 47,35 | 135,55k | -5,35% |
| 2025-12-02 | Mr. Marc A. StapleyCEO & Director | -7,91k | 365,31k | Sale to Issuer | 46,16 | 135,55k | -5,52% |
| 2025-12-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2,96k | 136,40k | Sale to Issuer | 46,16 | 16,29k | -15,36% |
| 2025-12-02 | Mr. Jonathan WygantVP & CAO | -1,33k | 61,16k | Sale to Issuer | 46,16 | 4,26k | -23,74% |
| 2025-12-04 | Ms. Rebecca ChambersExec. VP & CFO | -13,28k | 621,96k | Automatic Disposition | 46,61 - 47,25 | 36,20k | -26,84% |
| 2025-12-02 | Ms. Rebecca ChambersExec. VP & CFO | -3,38k | 156,21k | Sale to Issuer | 46,16 | 36,20k | -8,55% |
| 2025-12-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -1,42k | 67,26k | Automatic Disposition | 47,10 - 47,51 | 11,50k | -11,01% |
| 2025-12-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3,05k | 140,88k | Sale to Issuer | 46,16 | 11,50k | -20,98% |
| 2025-12-04 | Dr. John LeiteGlobal Chief Commercial Officer | -1,28k | 60,72k | Automatic Disposition | 47,51 | 8,07k | -13,67% |
| 2025-12-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2,90k | 133,86k | Sale to Issuer | 46,16 | 8,07k | -26,44% |
| 2025-11-25 | Dr. John LeiteGlobal Chief Commercial Officer | -2,81k | 140,40k | Automatic Disposition | 50,00 | 6,54k | -30,04% |
| 2025-11-25 | Mr. Evan JonesIndependent Director | -1,11k | 55,58k | Automatic Disposition | 50,25 | 20,04k | -5,23% |
| 2025-11-20 | Mr. Jens H. HolsteinIndependent Director | -10,00k | 423,56k | Automatic Disposition | 40,95 - 43,21 | 17,88k | -35,87% |
| 2025-11-07 | Mr. Jonathan WygantVP & CAO | -10,92k | 449,91k | Vente | 40,21 - 42,33 | 2,78k | -79,70% |
| 2025-11-05 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6,47k | 258,64k | Automatic Disposition | 40,00 | 9,96k | -39,36% |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -30,00k | 1,13M | Derivative Exercise and Sale | 5,28 - 45,73 | 21,15k | - |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -13,20k | 603,84k | Automatic Disposition | 45,73 - 46,38 | 21,15k | -38,42% |
| 2025-11-05 | Ms. Karin EasthamIndependent Director | -9,67k | 387,19k | Automatic Disposition | 40,02 | 4,23k | -69,56% |
| 2025-11-05 | Ms. Rebecca ChambersExec. VP & CFO | -7,00k | 287,00k | Automatic Disposition | 41,00 | 46,20k | -13,16% |
| 2025-10-06 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -8,35k | 300,71k | Automatic Disposition | 36,02 | 13,43k | -38,34% |
| 2025-10-01 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2,16k | 75,61k | Automatic Disposition | 35,00 | 16,43k | -11,62% |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -10,00k | 271,37k | Derivative Exercise and Sale | 7,94 - 35,08 | 53,13k | - |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -11,47k | 402,44k | Automatic Disposition | 35,08 | 53,13k | -17,76% |
| 2025-10-01 | Dr. John LeiteGlobal Chief Commercial Officer | -2,54k | 88,87k | Automatic Disposition | 35,00 | 9,35k | -21,36% |
| 2025-09-19 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2,28k | 76,92k | Automatic Disposition | 33,69 | 18,59k | -10,94% |
| 2025-09-04 | Mr. Marc A. StapleyCEO & Director | -7,67k | 233,13k | Automatic Disposition | 30,41 | 135,55k | -5,35% |
| 2025-09-02 | Ms. Rebecca ChambersExec. VP & CFO | -5,37k | 161,72k | Sale to Issuer | 30,11 | 53,20k | -9,17% |
| 2025-09-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3,51k | 105,60k | Sale to Issuer | 30,11 | 20,87k | -14,39% |
| 2025-09-02 | Mr. Marc A. StapleyCEO & Director | -7,91k | 238,29k | Sale to Issuer | 30,11 | 143,22k | -5,24% |
| 2025-09-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2,96k | 88,98k | Sale to Issuer | 30,11 | 21,78k | -11,95% |
| 2025-09-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2,90k | 87,38k | Sale to Issuer | 30,11 | 11,89k | -19,62% |
| 2025-09-02 | Mr. Jonathan WygantVP & CAO | -1,65k | 49,62k | Sale to Issuer | 30,11 | 13,70k | -10,74% |
| 2025-06-13 | Ms. Karin EasthamIndependent Director | -4,59k | 122,39k | Automatic Disposition | 26,66 | 13,91k | -24,81% |
| 2025-06-13 | Ms. Muna BhanjiIndependent Director | -4,59k | 122,37k | Automatic Disposition | 26,67 | 29,99k | -13,27% |
| 2025-06-04 | Dr. John LeiteGlobal Chief Commercial Officer | -2,81k | 76,41k | Automatic Disposition | 27,20 | 9,08k | -23,63% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
